
Sign up to save your podcasts
Or


GRAALL-2005 study shows no overall benefit for cyclophosphamide intensification in older adults with ALL, despite a general improvement in outcomes for the younger adults.
Read the associated article by Huguet et al on JCO.org.
By American Society of Clinical Oncology (ASCO)3.8
3939 ratings
GRAALL-2005 study shows no overall benefit for cyclophosphamide intensification in older adults with ALL, despite a general improvement in outcomes for the younger adults.
Read the associated article by Huguet et al on JCO.org.

14,364 Listeners

137 Listeners

320 Listeners

498 Listeners

58 Listeners

112,758 Listeners

44 Listeners

32 Listeners

195 Listeners

90 Listeners

364 Listeners

253 Listeners

189 Listeners

41 Listeners

613 Listeners